Document is current
Any future updates will be listed below
-
Authors
Siegel, Patrick M.
Katzmann, Julius L.
Weinmann-Menke, Julia
Landmesser, Ulf
Schunkert, Heribert
Baldus, Stephan
Böhm, Michael
Laufs, Ulrich
Lüscher, Thomas F.
Hilgendorf, Ingo
-
Funding
Funding for this research was provided by:
Universitäts-Herzzentrum Freiburg - Bad Krozingen GmbH
- License Information
-
More Information
Article History
Received: 18 October 2025
Accepted: 2 December 2025
First Online: 8 January 2026
Declarations
:
: PS consulted for Novartis, and HS consulted for AstraZeneca, BayerVital, Daiichi Sankyo, MSD/Merck, Novartis, Sanofi, Servier, Amgen and Takeda Pharma. JLK received honoraria and/or travel grants from Daiichi Sankyo, Novartis, Synlab, Boehringer Ingelheim, and Lilly. UL received honoraria from Amgen, Daiichi Sankyo, Novartis, and Sanofi. UL received research support or payment from Abbott, Amgen, Novartis, Merck Sharp&Dohme, Sanofi, Menarini from Amgen, Daiichi Sankyo, Novartis, and Sanofi. TFL does not accept any honoraria from industry, but received educational and research grants from Abbott, Amgen, Alnylam, AstraZeneca, BAYER, Boehringer Ingelheim, Cytokinetics, Daichi-Sankyo, Eli Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, and Vifor.The manuscript reflects some of the ideas discussed at the 38th Symposium of the Walter-Siegenthaler-Gesellschaft 2024 in Cologne entitled “The pharmacologic revolution – nuclear acids as therapeutic agents in internal medicine”.
